Topics

Breakthrough Therapy status granted to abatacept to prevent acute GvHD

04:45 EST 5 Dec 2019 | SmartBrief

Bristol-Myers Squibb announced that the FDA has granted its drug Orencia, or abatacept, Breakthrough Therapy designation as a -More

Original Article: Breakthrough Therapy status granted to abatacept to prevent acute GvHD

NEXT ARTICLE

More From BioPortfolio on "Breakthrough Therapy status granted to abatacept to prevent acute GvHD"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...